{"id":"https://openalex.org/W1993628347","doi":"https://doi.org/10.1177/0269881109106953","title":"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR","display_name":"Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR","alternate_titles":[],"publication_year":2009,"publication_date":"2009-11-25","ids":{"openalex":"https://openalex.org/W1993628347","doi":"https://doi.org/10.1177/0269881109106953","mag":"1993628347","pmid":"https://pubmed.ncbi.nlm.nih.gov/19939870"},"language":"en","primary_location":{"id":"doi:10.1177/0269881109106953","doi":"https://doi.org/10.1177/0269881109106953","is_oa":false,"landing_page_url":"https://doi.org/10.1177/0269881109106953","pdf_url":null,"source":{"id":"https://openalex.org/S136368880","display_name":"Journal of Psychopharmacology","issn_l":"0269-8811","issn":["0269-8811","1461-7285"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Psychopharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1993628347"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061767934","display_name":"Karen Hewett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Karen Hewett","raw_affiliation_strings":["GlaxoSmithKline, Harlow, UK,","GlaxoSmithKline, Harlow, UK, Karen.Hewett@gsk.com#N#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Harlow, UK,","institution_ids":["https://openalex.org/I188950975"]},{"raw_affiliation_string":"GlaxoSmithKline, Harlow, UK, Karen.Hewett@gsk.com#N#","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108202558","display_name":"Michelle Gee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michelle D Gee","raw_affiliation_strings":["GlaxoSmithKline, Harlow, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Harlow, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010255066","display_name":"Alok Krishen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alok Krishen","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, USA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046195067","display_name":"Hans-Peter Wunderlich","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I78650965","display_name":"Technische Universit\u00e4t Dresden","ror":"https://ror.org/042aqky30","country_code":"DE","type":"education","lineage":["https://openalex.org/I78650965"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hans-Peter Wunderlich","raw_affiliation_strings":["Akademische Lehrpraxis an der Technischen Universit\u00e4t Dresden, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Akademische Lehrpraxis an der Technischen Universit\u00e4t Dresden, Germany","institution_ids":["https://openalex.org/I78650965"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065927734","display_name":"Alfred Le Clus","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alfred Le Clus","raw_affiliation_strings":["Private Practice, Kempton Park, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Private Practice, Kempton Park, South Africa","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085684286","display_name":"Gary E. Evoniuk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gary Evoniuk","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, USA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5025148574","display_name":"Jack G. Modell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jack G Modell","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, USA","institution_ids":["https://openalex.org/I4210114143"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4400,"currency":"USD","value_usd":4400},"apc_paid":null,"fwci":3.1555,"has_fulltext":false,"cited_by_count":75,"citation_normalized_percentile":{"value":0.90079426,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"24","issue":"8","first_page":"1209","last_page":"1216"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10272","display_name":"Mental Health Treatment and Access","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bupropion","display_name":"bupropion","score":0.8840000033378601},{"id":"https://openalex.org/keywords/venlafaxine","display_name":"venlafaxine","score":0.996999979019165},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.9210000038146973},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.9200000166893005},{"id":"https://openalex.org/keywords/antidepressant-tolerability","display_name":"antidepressant tolerability","score":0.8450000286102295},{"id":"https://openalex.org/keywords/extended-release-formulation","display_name":"sustained-release formulation","score":0.9089999794960022},{"id":"https://openalex.org/keywords/serotonin-norepinephrine-reuptake-inhibitors","display_name":"serotonin-norepinephrine reuptake inhibitors","score":0.9940000176429749},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.6970000267028809},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.5550000071525574},{"id":"https://openalex.org/keywords/sexual-dysfunction","display_name":"sexual dysfunction","score":0.5820000171661377},{"id":"https://openalex.org/keywords/xerostomia","display_name":"xerostomia","score":0.5649999976158142},{"id":"https://openalex.org/keywords/insomnia","display_name":"insomnia","score":0.7820000052452087},{"id":"https://openalex.org/keywords/hyperhidrosis","display_name":"hyperhidrosis","score":0.9229999780654907}],"concepts":[{"id":"https://openalex.org/C2779908668","wikidata":"https://www.wikidata.org/wiki/Q834280","display_name":"Bupropion","level":3,"score":0.6947811841964722},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6846096515655518},{"id":"https://openalex.org/C2776466888","wikidata":"https://www.wikidata.org/wiki/Q898407","display_name":"Venlafaxine","level":4,"score":0.6383703947067261},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6069399118423462},{"id":"https://openalex.org/C2909532165","wikidata":"https://www.wikidata.org/wiki/Q898407","display_name":"Venlafaxine Hydrochloride","level":5,"score":0.6041510105133057},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.5154593586921692},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.48256033658981323},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.45219478011131287},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42428362369537354},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.40720242261886597},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.20495611429214478},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C2777843972","wikidata":"https://www.wikidata.org/wiki/Q2462253","display_name":"Smoking cessation","level":2,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069470","descriptor_name":"Venlafaxine Hydrochloride","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016642","descriptor_name":"Bupropion","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016642","descriptor_name":"Bupropion","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D016642","descriptor_name":"Bupropion","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1177/0269881109106953","doi":"https://doi.org/10.1177/0269881109106953","is_oa":false,"landing_page_url":"https://doi.org/10.1177/0269881109106953","pdf_url":null,"source":{"id":"https://openalex.org/S136368880","display_name":"Journal of Psychopharmacology","issn_l":"0269-8811","issn":["0269-8811","1461-7285"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:19939870","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19939870","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of psychopharmacology (Oxford, England)","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W19903215","https://openalex.org/W62065237","https://openalex.org/W108869947","https://openalex.org/W174997755","https://openalex.org/W1867335213","https://openalex.org/W2002388246","https://openalex.org/W2006170936","https://openalex.org/W2008979600","https://openalex.org/W2009578329","https://openalex.org/W2018434620","https://openalex.org/W2029297015","https://openalex.org/W2046809238","https://openalex.org/W2076391934","https://openalex.org/W2082205780","https://openalex.org/W2087237399","https://openalex.org/W2095000678","https://openalex.org/W2096527989","https://openalex.org/W2106158410","https://openalex.org/W2140787893","https://openalex.org/W2145911019","https://openalex.org/W2163016393","https://openalex.org/W2412172055","https://openalex.org/W4249121523"],"related_works":["https://openalex.org/W2029297015","https://openalex.org/W2076391934","https://openalex.org/W1991296006","https://openalex.org/W2068083208","https://openalex.org/W2017331101","https://openalex.org/W2164706851","https://openalex.org/W1994320961","https://openalex.org/W1975870015","https://openalex.org/W1992828484","https://openalex.org/W2041966651"],"abstract_inverted_index":{"Bupropion,":[0],"a":[1,7],"noradrenaline/dopamine":[2],"reuptake":[3,9],"inhibitor,":[4,10],"and":[5,30,40,145,147,166,171,178,180,193,196,216,238],"venlafaxine,":[6],"serotonin/noradrenaline":[8],"are":[11],"both":[12],"established":[13],"antidepressants":[14,50],"with":[15,52,55,64,94,125,228,248],"proven":[16],"efficacy":[17,39],"in":[18,222,242],"randomized":[19,60],"controlled":[20],"clinical":[21],"trials.":[22],"The":[23],"objective":[24],"of":[25,42,47,75,119,206,234],"this":[26,109],"double-blind,":[27],"randomized,":[28],"placebo-":[29],"active-controlled,":[31],"eight-week,":[32],"flexible-dose":[33],"study":[34],"was":[35,106],"to":[36,61,92,97],"evaluate":[37],"the":[38,43,72,95,99,189,202,223,243],"tolerability":[41],"once-daily":[44,62],"extended-release":[45,73],"formulations":[46],"these":[48],"two":[49],"compared":[51,124],"placebo.":[53],"Patients":[54],"major":[56],"depressive":[57],"disorder":[58],"were":[59,197,220,240],"treatment":[63],"bupropion":[65,111,244],"XR":[66,112,154,225,245],"150":[67],"mg":[68,80],"(n":[69,81,86],"=":[70,82,87],"204),":[71],"formulation":[74],"venlafaxine":[76,153,224],"(venlafaxine":[77],"XR)":[78],"75":[79],"198)":[83],"or":[84,138],"placebo":[85,126,158],"189)":[88],"during":[89],"weeks":[90],"1":[91],"4,":[93],"option":[96],"double":[98],"dose":[100],"at":[101,163,201],"week":[102,128,164],"5":[103],"if":[104],"response":[105],"inadequate.":[107],"In":[108],"study,":[110],"did":[113],"not":[114],"demonstrate":[115],"statistically":[116],"significant":[117],"evidence":[118],"greater":[120],"improvement":[121,187],"from":[122],"baseline":[123],"on":[127,139,159,172,188],"8":[129,165],"Montgomery":[130],"Asberg":[131],"Depression":[132],"Rating":[133],"scale":[134],"scores":[135,162],"(primary":[136],"endpoint)":[137],"secondary":[140],"endpoints":[141,174],"including":[142,175],"CGI,":[143,176],"HAM-A":[144,177],"responder":[146,179],"remitter":[148,181],"analyses.":[149,182],"Descriptive":[150],"statistics":[151],"for":[152],"indicated":[155],"separation":[156],"versus":[157],"MADRS":[160],"total":[161],"other":[167,173],"intermediate":[168],"time":[169],"points,":[170],"Both":[183],"active":[184],"treatments":[185],"elicited":[186],"Sheehan":[190],"Disability":[191],"Scale":[192],"its":[194,229,249],"subscales":[195],"generally":[198],"well":[199],"tolerated":[200],"doses":[203],"studied.":[204],"Rates":[205,233],"nausea,":[207],"dry":[208,235],"mouth,":[209,236],"dizziness,":[210],"hyperhidrosis,":[211],"insomnia,":[212],"constipation,":[213],"tremor,":[214],"anorexia":[215],"male":[217],"sexual":[218],"dysfunction":[219],"elevated":[221,241],"group,":[226,246],"consistent":[227,247],"mixed":[230],"serotonergic/noradrenergic":[231],"mechanism.":[232,251],"insomnia":[237],"hyperhidrosis":[239],"catecholaminergic":[250]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1993628347","counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
